Market Pulse Archives

July 14, 2022, 9:11 a.m. EDT

Marinus to sell rare-disease voucher to Novo Nordisk for $110 million

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Marinus Pharmaceuticals Inc. (MRNS)
  • X
    Novo Nordisk A/S ADR (NVO)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Marinus Pharmaceuticals Inc. /zigman2/quotes/208112000/composite MRNS +6.72% gained 7.9% in premarket trading on Thursday after the company said it plans to sell its Rare Pediatric Disease Priority Review Voucher for $110 million to Novo Nordisk /zigman2/quotes/203484366/composite NVO +1.77% . Marinus CFO Steven Pfanstiel told investors in a news release that the sale "extends our cash runway into the fourth quarter of 2023." Marinus received the voucher in March after it received approval from the Food and Drug Administration for Ztalmy, its treatment for seizures associated with a rare form of epilepsy. The company's stock has tumbled 53.3% this year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.49% is down 20.3%.

/zigman2/quotes/208112000/composite
US : U.S.: Nasdaq
$ 4.29
+0.27 +6.72%
Volume: 128,965
Dec. 8, 2022 2:29p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$191.85 million
Rev. per Employee
$175,540
loading...
/zigman2/quotes/203484366/composite
US : U.S.: NYSE
$ 127.46
+2.22 +1.77%
Volume: 626,057
Dec. 8, 2022 2:28p
P/E Ratio
37.87
Dividend Yield
0.89%
Market Cap
$282.60 billion
Rev. per Employee
$508,402
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,953.35
+19.43 +0.49%
Volume: 0.00
Dec. 8, 2022 2:29p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.